Abstract
Introduction
Until now, there was no validated and reliable tool to estimate life expectancy among patients with cancer-associated hypercalcemia (CAH). This study aimed to validate a prognostic score previously published.
Methods
We studied a new cohort of 252 patients with CAH. Our prognostic score based on the four poor-prognosis factors (liver metastasis, squamous cell carcinoma, hypoalbuminemia, and calcemia >2.83 mmol) was implemented to this cohort. The accuracy of this score for the prediction of 90-day mortality was estimated with area under the curve of the receiver operator curve (AUC-ROC).
Results
Among this validation cohort, patients with score = 0 experienced a median overall survival of 797 days; whereas, patients with score ≥1 (at least one poor-prognosis factor) had median overall survival of 49 days (p < 0.0001). The AUC-ROC for the prediction of 90-day mortality were 0.88 (0.76–0.86) and 0.67 (0.61–0.74) in the development cohort and in the validation cohort, respectively.
Conclusion
We have validated a reliable bedside prognostic score for CAH.
This is a preview of subscription content, log in via an institution to check access.
References
Augustson BM, Begum G, Dunn JA et al (2005) Early mortality after diagnosis of multiple myeloma analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002—Medical Research Council Adult Leukemia Working Party. J Clin Oncol 23:9219–9226
Body JJ, Borkowski A, Cleeren A, Bijvoet OL (1986) Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate. J Clin Oncol 4:1177–1183
Cvitkovic F, Armand JP, Tubiana-Hulin M, Rossi JF, Warrell RP Jr (2006) Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia. Cancer J 12:47–53
Major P, Lhortolary A, Hon J et al (2001) Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two-randomized controlled clinical trials. J Clin Oncol 19:558–567
Nussbaum SR, Younger J, Vandepol CJ et al (1993) Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med 95:297–304
Penel N, Dewas S, Doutrelant P, Clisant S, Yazdanpanah Y, Adenis A (2008) Cancer-associated hypercalcemia treated by intravenous diphosphonates: a survival and prognostic factor analysis. Support Care Cancer 16:387–392
Penel N, Vanseymortier M, Bonneterre ME et al (2008) Prognostic factors among patients with good performance status screened for phase I trials. Invest New Drugs 26:53–58
Rades D, Dunst J, Schild SE (2008) The first score predicting overall survival in patients with metastatic spinal cord compression. Cancer 112:157–161
Rassi A Jr, Rassi A, Little WC et al (2006) Development and validation of a risk score for predicting death in Chaga’s heart disease. N Engl J Med 355:799–808
Sather H (1986) The use of prognostic factors in clinical trials. Cancer 58:461–467
Tanko LB, Karsdal MA, Christiansen C, Leeming DJ (2006) Biochemical approach to the detection and monitoring of metastatic bone disease: what do we know and what questions need answers? Cancer Metastasis Rev 25:659–668
Vinholes J, Guo CY, Purohit OP, Eastell R, Coleman RE (1997) Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy. J Clin Oncol 15:131–138
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Penel, N., Dewas, S., Hoffman, A. et al. Cancer-associated hypercalcemia: validation of a bedside prognostic score. Support Care Cancer 17, 1133–1135 (2009). https://doi.org/10.1007/s00520-009-0607-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-009-0607-5